<?xml version='1.0' encoding='utf-8'?>
<document id="15572720"><sentence text="Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis."><entity charOffset="97-109" id="DDI-PubMed.15572720.s1.e0" text="cerivastatin" /></sentence><sentence text="In recent years, US patients have increasingly been the first to receive new medications, some of which are subsequently discovered to have suspected adverse drug reactions (SADRs)" /><sentence text=" As a result, the challenge of early detection has largely shifted to the US postmarketing systems" /><sentence text="" /><sentence text="To review the association between the use of cerivastatin sodium and the risk of rhabdomyolysis in an effort to illustrate the operation and limitations of the current US postmarketing safety-surveillance system"><entity charOffset="45-64" id="DDI-PubMed.15572720.s5.e0" text="cerivastatin sodium" /></sentence><sentence text="" /><sentence text="For the published literature, we used previous reviews and MEDLINE searches from all years through 2003" /><sentence text=" For the unpublished literature, we used internal company documents that have become part of the public record during a trial in Nueces County, Texas" /><sentence text="" /><sentence text="In the published literature, cerivastatin was associated with much larger risks of rhabdomyolysis than other statins"><entity charOffset="29-41" id="DDI-PubMed.15572720.s10.e0" text="cerivastatin" /></sentence><sentence text=" Although only a small percentage of cerivastatin users also took gemfibrozil, approximately half of the case reports of rhabdomyolysis occurred in users of this combination therapy, and a cerivastatin-gemfibrozil interaction was supported by the results of a 3-day pharmacokinetic study"><entity charOffset="37-49" id="DDI-PubMed.15572720.s11.e0" text="cerivastatin" /><entity charOffset="66-77" id="DDI-PubMed.15572720.s11.e1" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.15572720.s11.e0" e2="DDI-PubMed.15572720.s11.e0" /><pair ddi="false" e1="DDI-PubMed.15572720.s11.e0" e2="DDI-PubMed.15572720.s11.e1" /></sentence><sentence text=" In internal company documents, multiple case reports suggested a drug-drug interaction within approximately 100 days of the launch in 1998; however, the company did not add a contraindication about the concomitant use of cerivastatin and gemfibrozil to the package insert for more than 18 months"><entity charOffset="222-234" id="DDI-PubMed.15572720.s12.e0" text="cerivastatin" /><entity charOffset="239-250" id="DDI-PubMed.15572720.s12.e1" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.15572720.s12.e0" e2="DDI-PubMed.15572720.s12.e0" /><pair ddi="false" e1="DDI-PubMed.15572720.s12.e0" e2="DDI-PubMed.15572720.s12.e1" /></sentence><sentence text=" Unpublished data available in July 1999 also suggested an increased risk of rhabdomyolysis associated with high doses of cerivastatin monotherapy"><entity charOffset="122-134" id="DDI-PubMed.15572720.s13.e0" text="cerivastatin" /></sentence><sentence text=" In late 1999 and early 2000, company scientists conducted high-quality analyses of the US Food and Drug Administration adverse event reporting system data" /><sentence text=" These analyses suggested that compared with atorvastatin calcium, cerivastatin monotherapy substantially increased the risk of rhabdomyolysis"><entity charOffset="45-65" id="DDI-PubMed.15572720.s15.e0" text="atorvastatin calcium" /><entity charOffset="67-79" id="DDI-PubMed.15572720.s15.e1" text="cerivastatin" /><pair ddi="false" e1="DDI-PubMed.15572720.s15.e0" e2="DDI-PubMed.15572720.s15.e0" /><pair ddi="false" e1="DDI-PubMed.15572720.s15.e0" e2="DDI-PubMed.15572720.s15.e1" /></sentence><sentence text=" To our knowledge, these findings were not disseminated or published" /><sentence text=" The company continued to conduct safety studies, some of them inadequately designed to assess the risk of rhabdomyolysis, until cerivastatin was removed from the market in August 2001"><entity charOffset="129-141" id="DDI-PubMed.15572720.s17.e0" text="cerivastatin" /></sentence><sentence text="" /><sentence text="Despite limitations of the available data, the asymmetry between the information available to the company and the information available to patients and physicians seems striking" /><sentence text=" A subjective element is present in the effort to infer whether or not the occurrence of untoward outcomes in users of a particular drug was actually the consequence of the use of that drug, and, under the current system, a pharmaceutical company's appraisal of SADRs may be influenced by economic considerations" /><sentence text=" Such an appraisal would best be made by an independent group" /><sentence text=" The US Congress should mandate and provide adequate support for independent reviews and analysis of postmarketing data" /><sentence text="" /></document>